UroGen Pharma Ltd. (NASDAQ:URGN) is expected to report second quarter earnings results, before market open, on Monday 10th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 1.58 per share from revenue of $ 0.26 million.
Looking ahead, the full year loss are expected at $ 6.23 per share on the revenues of $ 12.55 million.
Previous Quarter Performance
UroGen Pharma Ltd. posted loss for the first quarter of $ 1.79 per share, from the revenue of . The quarterly earnings while revenues compared with the same quarter last year.
According to street consensus, loss of $ 1.62 was expected per share The bottom line results missed street analysts by $ 0.17 or 10.49 percent, at the same time, top line results analysts by $ 1.01 million or .
Stock Performance
According to the previous trading day, closing price of URGN was $ 23.16, representing a 76.52 % increase from the 52 week low of $ 13.12 and a 37.54 % decrease over the 52 week high of $ 37.08.
The company has a market capital of $ 508.02 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”URGN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
UroGen Pharma Ltd. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.urogen.com
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The companys lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.
